ASH 2017 | How do we sequence and combine novel agent-based therapies in CLL?
Matthew Davids
• 9 Dec 2017
There are now many drugs available for the treatment of chronic lymphocytic leukemia (CLL); however, there is only limited data regarding the best order and combination to administer them in. Here, Matthew Davids, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the factors that can be used to determine what therapeutic agent is the best choice. Dr Davids covers sequencing to detect specific mutations, such as those in the TP53 and IGHV genes. He also highlights what variables should be considered in patients without these more well-characterized mutations. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
